TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Gravitricity is an energy technology company. The company uses winches to raise a heavyweight to the top of a vertical shaft to store electricity in the form of potential energy when there is excess energy on the grid. It then lowers it when required with the winch motors running as generators to transfer energy back to users on the grid. Gravitricity argues that the system can be charged and discharged multiple times a day for over 25 years. The company has built a 250kW concept demo in Edinburgh. It aims to become a contender in the energy storage market that is set to be worth $620 billion by 2040. The company has received interest from operating mines, grid companies, EV charging stations and solar developers for its technology. It is also investigating project sites in UK, Europe, the USA and South Africa. It will use the investment to complete the concept and detailed design for its prototype, develop its commercial projects portfolio, and protect its Intellectual Property (IP).
days to go:
Expired
investment:
£2,124,008
Greenwall Environmental Group is a company engaged in making devices that can minimise non-biodegradable waste. It argues that asbestos remains the largest occupational killer in the UK today. Its product, Asbestosprobe, aims to change this situation. The company asserts that Asbestoprobe is arguably the world's first handheld analyser specifically designed to detect asbestos in real-time. It argues that current methods of detecting and recording the presence of asbestos are costly, invasive and slow. Asbestoprobe uses a point-and-click approach utilising NIR Spectroscopy and Artificial Intelligence (AI) to analyse the presence of asbestos in two minutes via the Asbestoprobe App. Greenwall plans to provide an annual software licensing model which grows through recurring revenue year on year. It endeavours to be a segment leader in the projected $1 billion global asbestos management market. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£253,017
Crover intends to leverage the world's first proprietary method for locomotion in bulk solids. It argues that globally, 20% (60% in developing areas) of harvested grains are wasted during storage that led to almost 631 million tonnes of grains being wasted in 2018. Crover claims CROVER, its robotic grain monitoring device, can fluently “swim” in stored grains, monitor their conditions, reduce losses due to spoilage and avoid a drop in quality of these valuable crops. The company argues CROVER can provide hi-resolution readings across the storage unit and help hinder pest growth, allowing for early detection of potential spoilage. Crover was awarded £614,000 in grant funding including, £212,000 from Innovate UK. It has featured in publications such as The Times, Farmers Weekly, and Milling & Grain. They intend to use the investment to begin arranging and readying parties regarding new pilot programmes and begin small series manufacturing for these pilot schemes.
days to go:
Expired
investment:
£337,762
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen £14 million worth of investment on its portal to date. Brickowner will use the investment towards technology up-gradation, hire strategic personnel to expand marketing, and increase its marketing spend.
days to go:
Expired
investment:
£132,528
Nova is a world-leading and award-winning tidal energy company. It designs, builds, and operates tidal turbines that generate electricity from the flow of the tide and the natural ebb. Nova's underwater turbines work in harmony with marine environment and have zero visual impact. In 2018, Nova received international recognition at the G7 summit and won ‘Outstanding Project’ at the Green Energy Awards the same year. Nova aims to become cost-competitive with traditional baseload fossil fuels. With the proceeds, the company will fulfil its purpose of Business Growth (25%), Project Delivery (50%), and Commercial Readiness (25%).
days to go:
Expired
investment:
£1,255,666
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company asserts that it undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen over £15 million worth of investments on its portal till date. Brickowner will use the investment towards technology up-gradation, develop its B2B capacity, and increase marketing initiatives to support company growth
days to go:
Expired
investment:
£290,362
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.
days to go:
Expired
investment:
£118,950
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
